Typicality: | 0.308 |
Saliency: | 0.136 |
by a potential pharmaceutical manufacturer | 2 | other |
trial → be conducted by → the national cancer institute | 4 |
trial → be led by → the national cancer institute | 3 |
negative | neutral | positive |
0.044 | 0.794 | 0.162 |
Raw frequency | 7 |
Normalized frequency | 0.136 |
Modifier score | 0.500 |
Perplexity | 15.674 |